

**Table 1: Tumour size at baseline**

Tumour Characteristics	Active	Placebo	Total
<b>Tumour size (mm)*</b>			
<b>N</b>	75	75	150
<b>Mean</b>	4.47	4.00	4.23
<b>St. Dev</b>	1.61	1.56	1.59
<b>Median</b>	4	4	4
<b>IQR, Range</b>	IQR(3,5) R(2,11)	IQR(3,5) R(2,10)	IQR(3,5) R(2,11)
<b>Location (N %)</b>	75	75	150
Trunk	5 (6.7)	5 (6.7)	10 (6.7)
Face and Neck	41 (54.7)	39 (52.0)	80 (53.3)
Scalp	29 (38.7)	31 (41.3)	60 (40.0)
Limbs	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)
<b>Appearance (N %)</b>	75	75	150
Hairy	34 (45.3)	36 (48.0)	70 (46.7)
Non-hairy	40 (53.3)	39 (52.0)	79 (52.7)
Not applicable	1 (1.3)	0	1 (0.7)

15 participants enrolled onto cohort 2 had 10 tumours selected (5 from right hand side and 5 from the left hand side of the body). The diameters of the 150 tumours selected were measured by a ruler. As indicated by table 1, 75 tumours were treated with CT327 ointment and the remaining 75 with placebo ointment. The study investigator, study team and participants were all blinded to the which sides received treatment and placebo.

**Table 2: Tumour measurements at baseline, week 4 and week 12 in cohort 2**

		n	mean	95% CI	median	IQR
<b>OVERALL</b>	height	150	0.74	(0.68, 0.81)	0.64	(0.47 , 0.91)
	Baseline surface area	150	28.62	(25.78, 31.47)	25.24	(15.50 , 35.78)
	Baseline volume	150	7.96	(6.36, 9.56)	4.66	(2.58 , 8.98)
	Week 4 height	140	0.78	(0.71, 0.86)	0.66	(0.49 , 0.99)
	Week 4 surface area	140	29.20	(26.11, 32.28)	25.47	(15.15 , 37.82)
	Week 4 volume	140	8.77	(6.80, 10.73)	5.01	(2.44 , 9.16)
	Week 12 height	140	0.78	(0.71, 0.86)	0.66	(0.47 , 1.00)
	Week 12 surface area	140	29.18	(26.08, 32.28)	25.79	(15.74 , 38.32)
	Week 12 volume	140	8.71	(6.75, 10.68)	4.80	(2.33 , 9.25)
<b>ACTIVE</b>	height	75	0.74	(0.65, 0.84)	0.65	(0.46 , 0.93)
	Baseline surface area	75	29.19	(25.28, 33.09)	26.49	(15.42 , 38.26)
	Baseline volume	75	8.12	(5.92, 10.33)	4.98	(2.57 , 9.40)
	Week 4 height	70	0.79	(0.69, 0.90)	0.65	(0.46 , 1.01)
	Week 4 surface area	70	30.04	(25.87, 34.22)	27.71	(14.95 , 39.38)
	Week 4 volume	70	8.99	(6.33, 11.65)	5.12	(2.26 , 11.41)
	Week 12 height	70	0.79	(0.68, 0.89)	0.67	(0.46 , 1.02)
	Week 12 surface area	70	29.80	(25.63, 33.97)	26.99	(15.57 , 39.06)
	Week 12 volume	70	8.83	(6.21, 11.47)	4.59	(1.95 , 10.92)
<b>PLACEBO</b>	height	75	0.74	(0.65, 0.83)	0.62	(0.50 , 0.91)
	Baseline surface area	75	28.06	(23.83, 32.29)	24.81	(16.44 , 34.54)
	Baseline volume	75	7.79	(5.42, 10.17)	4.38	(2.58 , 8.03)
	Week4 height	70	0.78	(0.67, 0.88)	0.68	(0.50 , 0.96)
	Week4 surface area	70	28.35	(23.72, 32.99)	25.24	(15.73 , 34.73)
	Week4 volume	70	8.54	(5.59, 11.49)	4.99	(2.48 , 7.90)
	Week 12 height	70	0.78	(0.67, 0.89)	0.65	(0.50 , 0.99)
	Week 12 surface area	70	28.56	(23.87, 33.25)	25.52	(15.88 , 34.43)
	Week 12 volume	70	8.59	(5.59, 11.59)	5.01	(2.48 , 8.26)

Tumour volume was measured on the predetermined identified tumours in each patient prior to randomisation and measured again and recorded on the same tumours at 4 and 12 weeks. Tumour measurements (mean of the three readings) have been reported descriptively as mean (standard deviation) median and IQR at baseline, 4 weeks and 12 weeks and by treatment received and overall.

**Table 3: Tumour measurements of hairy tumours at baseline, week 4 and week 12 in cohort 2**

		n	mean	95% CI	median	IQR
<b>ACTIVE</b>	height	34	0.87	(0.70, 1.04)	0.79	(0.52 , 1.15)
	Baseline					
	surface area	34	34.53	(27.56, 41.49)	29.23	(19.46 , 48.04)
	volume	34	11.26	(6.96, 15.56)	6.03	(3.42 , 17.12)
	height	32	0.94	(0.75, 1.13)	0.90	(0.52 , 1.38)
	Week 4					
	surface area	32	35.39	(27.76, 43.02)	29.82	(19.54 , 49.16)
	volume	32	12.87	(7.68, 18.07)	6.30	(2.62 , 19.75)
	height	32	0.93	(0.74, 1.12)	0.90	(0.50 , 1.31)
	Week 12					
	surface area	32	34.83	(27.26, 42.40)	29.94	(19.97 , 48.83)
	volume	32	12.74	(7.62, 17.85)	7.08	(3.16 , 18.64)
<b>PLACEBO</b>	height	36	0.84	(0.69, 0.99)	0.9	(0.52 , 1.04)
	Baseline					
	surface area	36	36.39	(29.11, 43.66)	30.41	(23.40 , 43.01)
	volume	36	11.29	(6.84, 15.75)	7.05	(3.43 , 11.48)
	height	34	0.92	(0.74, 1.10)	0.85	(0.60 , 1.20)
	Week4					
	surface area	34	37.33	(29.38, 45.28)	30.58	(21.48 , 43.09)
	volume	34	12.93	(7.35, 18.50)	7.59	(3.71 , 13.45)
	height	34	0.92	(0.74, 1.10)	0.76	(0.58 , 1.14)
	Week 12					
	surface area	34	37.62	(29.60, 45.63)	30.59	(22.61 , 44.44)
	volume	34	12.91	(7.23, 18.58)	8.06	(2.79 , 12.62)

**Table 4: Tumour measurements of non-hairy tumours at baseline, week 4 and week 12 in cohort 2**

		n	mean	95% CI	median	IQR
<b>ACTIVE</b>	height	40	0.64	(0.70, 1.04)	0.54	(0.46 , 0.79)
	Baseline					
	surface area	40	24.53	(27.56, 41.49)	22.22	(13.73 , 33.51)
	volume	40	5.46	(6.96, 15.56)	3.69	(1.79 , 6.60)
	height	38	0.67	(0.75, 1.13)	0.61	(0.43 , 0.87)
	Week 4					
	surface area	38	25.54	(27.76, 43.02)	21.71	(14.42 , 34.16)
	volume	38	5.72	(7.68, 18.07)	3.83	(1.83 , 6.57)
<b>ACTIVE</b>	height	38	0.66	(0.74, 1.12)	0.59	(0.46 , 0.80)
	Week 12					
	surface area	38	25.57	(27.26, 42.40)	21.76	(14.22 , 34.21)
	volume	38	5.56	(7.62, 17.85)	4.03	(1.93 , 6.10)
	height	39	0.65	(0.69, 0.99)	0.58	(0.48 , 0.72)
	Baseline					
	surface area	39	20.37	(29.11, 43.66)	18.52	(12.92 , 25.62)
	volume	39	4.56	(6.84, 15.75)	2.96	(1.89 , 5.79)
<b>PLACEBO</b>	height	36	0.64	(0.74, 1.10)	0.58	(0.46 , 0.75)
	Week4					
	surface area	36	19.88	(29.38, 45.28)	12.33	(21.48 , 25.85)
	volume	36	4.40	(7.35, 18.50)	3.11	(1.94 , 5.57)
	height	36	0.65	(0.74, 1.10)	0.59	(0.47 , 0.74)
	Week 12					
	surface area	36	20.00	(29.60, 45.63)	19.21	(12.40 , 26.13)
	volume	36	4.51	(7.23, 18.58)	3.32	(1.83 , 5.82)